LM Funding America Inc
Change company Symbol lookup
Select an option...
LMFA LM Funding America Inc
INVVY Indivior PLC
OSUR OraSure Technologies Inc
QUOT Quotient Technology Inc
DUK Duke Energy Corp
WAFD Washington Federal Inc
REML Credit Suisse X-Links Monthly Pay 2xLeveraged Mortgage REIT ETN
$NQG3010LMT Nasdaq Global Banks Large Mid Cap To
SRTS Sensus Healthcare Inc
LITB LightInTheBox Holding Co Ltd
Go

Financials : Diversified Financial Services | Small Cap Blend
Company profile

LM Funding America, Inc. is a specialty finance company. The Company provides funding to nonprofit community associations primarily located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. It offers incorporated nonprofit community associations (Associations), a range of financial products customized to each Association's financial needs. Its products include Original Product and New Neighbor Guaranty. Its Original Product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. The Company offers the New Neighbor Guaranty, wherein an Association assigns its indebtedness and accruals on its delinquent units to it in exchange for payments in an amount equal to the regular ongoing monthly or quarterly assessments for delinquent units when those amounts would be due to the Association.

Premarket

Last Trade
Delayed
$0.65
0.0364 (5.93%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$0.6136
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
239,459

10-day average volume:
900,191
239,459

Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

4:01 pm ET September 8, 2020 (BusinessWire) Print

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at the Morgan Stanley Virtual Global Healthcare Conference, H.C Wainwright Virtual Global Investment Conference and Cantor Virtual Global Healthcare Conference during the week of September 14.

Additional details can be found below:

H.C. Wainwright Virtual Global Investment Conference Date: Tuesday, September 15 Time: 12:00 noon Eastern Time Presenter: Ed Smith, Chief Financial Officer, and Dr. Joseph Hulihan, Chief Medical Officer Link to webcast: https://wsw.com/webcast/hcw7/register.aspx?conf=hcw7&page=mrns

Morgan Stanley Virtual Global Healthcare Conference Date: Tuesday, September 15 Time: 1:15 pm Eastern Time Presenter: Dr. Scott Braunstein, Chief Executive Officer, and Ed Smith, Chief Financial Officer Link to webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1362519&tp_key=5ef6204e02

Cantor Virtual Global Healthcare Conference Date: Thursday, September 17 Time: 2:00 pm Eastern Time Presenter: Dr. Scott Braunstein, Chief Executive Officer, and Ed Smith, Chief Financial Officer Link to webcast: https://www.webcaster4.com/Webcast/Page/2495/37404

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus has conducted the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005959/en/

SOURCE: Marinus Pharmaceuticals">

Sasha Damouni Ellis
Vice President, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.